Macrocyclic LRRK2 Kinase Inhibitors for Potency and Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Parkinson's disease, Alzheimer's disease, inflammatory disorders, and other conditions associated with LRRK2 kinase activity lack effective treatments to prevent, cure, or delay progression, and existing LRRK2 inhibitors do not meet the needs for potency and selectivity.
Innovation Solution
Development of novel macrocyclic compounds that act as selective LRRK2 kinase inhibitors, targeting specific domains to modulate kinase activity and address underlying disease mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing LRRK2 inhibitors are used, then some kinase inhibition activity is achieved, but potency and selectivity are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying molecular properties including macrocyclization to enhance potency and selectivity. The macrocyclic structure represents a specific structural parameter change that improves inhibitor effectiveness while maintaining reasonable complexity
Solution Approach 2:
The invention employs composite molecular structures combining multiple functional groups and structural elements within a macrocyclic framework. This composite approach integrates hydrophobic regions, hydrogen bonding capabilities, and specific stereochemical features to achieve superior kinase inhibition
2Ease of operation
If standard of care therapies are used, then symptomatic relief is achieved, but disease progression cannot be prevented or cured
Solution Approach 1:
The patent extracts and targets the underlying pathological mechanism by specifically inhibiting LRRK2 kinase activity, which is implicated in disease progression. This moves beyond symptomatic treatment to address the root cause, potentially preventing or delaying disease progression
Solution Approach 2:
The macrocyclic compounds act as intermediary molecules that specifically bind to and inhibit LRRK2 kinase, mediating the therapeutic effect between administration and disease modification. These compounds serve as the active intermediary that translates pharmacological intervention into disease progression prevention
Data Source
AI summary
Compounds of Formula (I):wherein R, X1, X2, X3, Z1, Z2, Z3, A and Ra are as defined in the description.